Analytical method is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical control focuses on protein content, hydrolysis extent, molecular weight distribution, and residual intact protein. Kjeldahl or Dumas methods measure total nitrogen, while size-exclusion chromatography or mass spectrometry estimates peptide profiles. Sodium dodecyl sulfate polyacrylamide gel electrophoresis can show remaining intact proteins, though small peptides may not resolve. Enzyme-linked immunosorbent assays are used to assess residual allergenic proteins in some contexts. Because no single method captures all relevant features, manufacturers combine several assays and report values against internal specifications.
Stability depends on moisture, temperature, oxygen, and packaging. Powdered hydrolysate generally requires cool, dry storage and protection from humidity because peptides can absorb water and undergo Maillard reactions with residual lactose. Higher temperatures can increase bitterness, discoloration, and loss of solubility over time, while liquid hydrolysate formats are more perishable and may need refrigeration or preservatives. Shelf-life studies typically monitor moisture, color, pH, protein solubility, and microbial counts. Exact stability limits vary by peptide profile, packaging, and water activity, so general rules should be treated as approximate.
Laboratories characterize hydrolyzed whey protein with several complementary assays. Total nitrogen methods, such as Kjeldahl or Dumas, estimate protein content using a dairy conversion factor. Free amino group assays, including TNBS and OPA, track the extent of peptide-bond cleavage. Size-exclusion chromatography and reversed-phase HPLC reveal peptide size distributions and hydrophobicity. Mass spectrometry can identify specific peptides, while amino acid analysis quantifies individual residues. No single test captures every relevant property, so results are usually interpreted together with process records and specification limits.
Quality control checks identity, composition, and contaminants. Moisture, ash, fat, and carbohydrate are measured by standard methods, and microbiological limits are set for total counts, coliforms, and specific pathogens. Heavy metals and pesticide residues may be monitored depending on market requirements. Adulteration with intact whey protein or individual amino acids is possible, so peptide fingerprints and free amino acid profiles can help verify authenticity. Regulatory frameworks vary: some countries treat hydrolyzed whey as a conventional dairy ingredient, while infant formula uses face additional compositional rules. Which marker peptides best confirm source and processing remains an open analytical question.
| Property | Value | Notes |
|---|---|---|
| Moisture content | ≤ 6% for powder | Lower moisture supports shelf stability |
| Water activity | Often below 0.3 | Higher values increase caking and browning |
| Typical storage temperature | 15–25 °C | Cool, dry, protected from humidity |
| Common analytical method | Size-exclusion chromatography | Estimates peptide molecular weight distribution |
| Bulk density | 0.3–0.6 g/mL | Depends on spray-drying and particle size |
Quality control focuses on degree of hydrolysis, molecular weight distribution, protein content, moisture, ash, and microbial limits. Degree of hydrolysis is commonly calculated from the number of cleaved peptide bonds relative to total peptide bonds. Size-exclusion chromatography and mass spectrometry can describe peptide size ranges, while amino acid analysis quantifies composition. Standard methods from dairy science organizations are often used, though no single method captures every functional property. Results are therefore reported alongside processing conditions.
Hydrolysates are generally stable as dry powders but can absorb moisture and undergo browning during warm storage. The bitter taste of some hydrolysates arises from hydrophobic peptides exposed by cleavage, and it varies with enzyme choice and degree of hydrolysis. Reduced allergenicity is sometimes claimed, but residual IgE-binding peptides may remain, especially in partial hydrolysates. Regulatory frameworks treat extensively hydrolyzed and partially hydrolyzed products differently, and labeling rules vary by country. More research is needed on how specific peptide profiles relate to clinical outcomes.
Commercial production begins with whey protein concentrate or isolate dissolved in water. A protease is added under controlled pH and temperature, and the reaction is stopped by heat or pH adjustment once a target degree of hydrolysis is reached. Membrane filtration, often ultrafiltration or diafiltration, removes enzymes and small solutes while retaining peptides. The liquid is then concentrated and spray-dried into a powder. Each step influences peptide length, mineral content, and flavor.
Quality control for hydrolysates often includes allergen and contaminant checks. Because whey is a milk-derived ingredient, milk protein residues may remain, and the extent to which hydrolysis reduces allergenic potential is product-specific and not fully predictable. Tests may screen for heavy metals, melamine, pesticides, and microbial indicators. Enzyme residues and processing aids are also monitored when regulations require it. Batch-to-batch consistency is assessed through peptide mapping or functional tests, since small process changes can alter taste, solubility, or nutritional performance.
Laboratories characterize whey protein hydrolysate by several complementary methods. Total nitrogen or Kjeldahl analysis estimates crude protein, while amino acid analysis gives a more detailed composition. Size-exclusion chromatography and mass spectrometry separate peptides by molecular weight and can reveal the distribution of chain lengths. Degree of hydrolysis is often calculated from free amino groups using trinitrobenzenesulfonic acid or o-phthaldialdehyde assays. No single measurement captures all relevant properties, so specifications usually combine protein content, peptide profile, moisture, ash, and microbial limits.
Storage stability depends on moisture, temperature, oxygen, and packaging. Dry hydrolysate powders are typically stable for months to years when kept cool and sealed, but they can absorb water and cake if exposed to humid air. Higher temperatures accelerate Maillard reactions between peptides and residual sugars, leading to browning and flavor changes. Lipid oxidation can occur if residual fat is present, producing off-odors. Once a powder is reconstituted, microbial growth becomes a concern, so liquid forms require refrigeration or other preservation steps.
Regulatory status differs by country and intended use. In many jurisdictions, whey protein hydrolysate is regulated as a food ingredient, while specific infant formula or medical food uses may require additional review. Labeling rules govern protein content claims, allergen statements, and terms such as partially hydrolyzed or extensively hydrolyzed. Analytical methods for degree of hydrolysis are not fully standardized, so values can depend on the assay. This variability makes direct comparison between products difficult unless the method and reference material are stated.
Quality control for whey protein hydrolysate begins with specification of protein, moisture, ash, fat, lactose, and degree of hydrolysis, while molecular weight distribution is measured by size-exclusion chromatography or electrophoresis. Free amino acid content can be quantified by amino acid analysis. Microbial limits, heavy metals, and residual enzyme activity are also monitored. Because hydrolysis conditions influence batch consistency, manufacturers validate processes and test each lot against release criteria. Sampling plans and reference standards help compare results across laboratories.
Hero Certified Burgers is a quick service restaurant franchise chain that operates in Canada, with locations concentrated in Southern Ontario. The chain was founded in 2004 by John Lettieri, who opened the first store in Hazelton Lanes in Yorkville, Toronto, Ontario. Lettieri also owns the restaurant chain Lettieri café, based in Toronto. The company was the first Canadian franchise to focus on the provision of fast foods using food products from vendors that adhere to sustainable practices.
== Water and wastewater treatment == Microbubbles have been investigated as an aeration technology for water and wastewater treatment, where their long residence time, high specific surface area, and capacity to generate reactive oxygen species can improve gas-transfer efficiency and contaminant removal compared with conventional diffused aeration. Reviews of microbubble and nanobubble aeration have reported improvements in dissolved oxygen levels and biological oxygen demand removal in activated sludge processes when these technologies are applied in place of conventional aeration.
==== Research and traditional medicine ==== Preliminary research indicates that the phytochemicals, betulin and possibly other triterpenes, are active in Episalvan gel and wound healing properties of birch bark. Over centuries, birch bark was used in traditional medicine practices by North American indigenous people for treating superficial wounds by applying bark directly to the skin. Splints made with birch bark were used as casts for broken limbs in the 16th century.
Sources: en.wikipedia.org
IPF is believed to be the result of an aberrant wound healing process including/involving abnormal and excessive deposition of collagen (fibrosis) in the pulmonary interstitium with minimal associated inflammation. Cellular senescence is suspected to be a central contributing cause, a belief which is supported by benefits seen in patients given senolytic therapy. It is hypothesized that the initial or repetitive injury in IPF occurs to the lung alveolar epithelial cells (pneumocytes), the type I and type II cells, which line the majority of the alveolar surface. When type I cells are damaged or lost, it is thought that type II cells undergo proliferation to cover the exposed basement membranes. In normal repair, the hyperplastic type II cells die and the remaining cells spread and undergo a differentiation process to become type I cells. Under pathologic conditions and in the presence of transforming growth factor beta (TGF-β), fibroblasts accumulate in these areas of damage and differentiate into myofibroblasts that secrete collagen and other proteins. In the current classification of the pathogenesis of IPF, it is believed that it occurs by way of the formation of a UIP (usual interstitial pneumonia) lesion, which then undergoes the aforementioned pathological condition characteristic of IPF. Other proposed repeated injury mechanisms indicate that IPF may result not just from a UIP lesion, but also from NSIP and DAD (nonspecific interstitial pneumonia and diffuse alveolar damage) lesions, or a combination of several.
=== US cold civil war === In spring 2017, professor emeritus Angelo Codevilla used the term "cold civil war" to criticize "the ruling class—government bureaucracies, the judiciary, academia, media, associated client groups, Democratic officials, and Democrat-controlled jurisdictions"—and what Codevilla considered "against a majority of the American people and their way of life." In 2017 and 2019, journalist Carl Bernstein criticized then-President Donald Trump, whom he called in 2019 "a sham, a con, a grifter [...] president of the United States", for exacerbating what Bernstein considered "cold civil war", citing in 2017 Trump administration's scapegoating of Hillary Clinton amid the Mueller special counsel investigation and in 2019 his efforts to appeal "prejudices" of his supporters toward "the other side" whom they wanted "wiped out". The Washington Post columnist Matt Bai in January 2021 used "a Cold Civil War" in reference to the US "imminent disunion", especially by rural Americans who "live increasingly in their own reality, nourished by their own 'alternative facts' and led by their own reckless leaders" and "separate themselves from [American] urban culture and establishment media". A media studies professor David A. Love in March 2021 criticized the US Republican Party for instigating "a cold civil war by pushing for unprecedented voter suppression measures targeting minority and marginalised communities".
Applications using this early discover were limited due to naturally low concentrations of this anti-haemophilic factor in blood and plasma and volume constraints in the circulatory system. In 1954, the Government wished to establish a site for increased production of blood products. This followed on from the importance of blood in therapeutic medicine, the need for blood products during the Second World War (particularly the use of albumin) and the formation on 26 September 1946 of the National Blood Transfusion Service. It had also been discovered that a second form of haemophilia (Haemophilia B) existed, which was treatable with blood protein called Factor IX. An agreement was reached between the Government, MRC and the Lister Institute and the Blood Products Laboratory was established with funding from the Ministry of Health. Enlarged facilities for plasma fractionation and freeze-drying were established. During the 1970s and early 1980s it became apparent that Factor VIII products produced at the BPL site (and other products from other companies) may have infected haemophiliacs with life-threatening viruses. Bigger risks to the patient population arose from U.S.imported products, a practice required since the UK was not self-sufficient in plasma products. In 1991 it was renamed the Bio Products Laboratory to reflect the internal market in the National Health Service and in 1993 it became part of the National Blood Authority. BPL began cross-charging NHS hospitals for its products and limited competition in the international blood plasma market was permitted.
=== EC 2.5.1: Transferring alkyl or aryl groups, other than methyl groups (only sub-subclass identified to date) === EC 2.5.1.1: dimethylallyltranstransferase EC 2.5.1.2: thiamine pyridinylase EC 2.5.1.3: thiamine-phosphate diphosphorylase EC 2.5.1.4: Now EC 4.4.1.42 adenosylmethionine cyclotransferase EC 2.5.1.5: galactose-6-sulfurylase EC 2.5.1.6: methionine adenosyltransferase EC 2.5.1.7: UDP-N-acetylglucosamine 1-carboxyvinyltransferase EC 2.5.1.8: transferred to EC 2.5.1.75, tRNA dimethylallyltransferase EC 2.5.1.9: riboflavin synthase EC 2.5.1.10: (2E,6E)-farnesyl diphosphate synthase EC 2.5.1.11: Now covered by EC 2.5.1.84 (all-trans-nonaprenyl-diphosphate synthase [geranyl-diphosphate specific]) and EC 2.5.1.85 (all-trans-nonaprenyl diphosphate synthase [geranylgeranyl-diphosphate specific]) EC 2.5.1.12: deleted, now included with EC 2.5.1.18 glutathione transferase EC 2.5.1.13: deleted, now included with EC 2.5.1.18 glutathione transferase EC 2.5.1.14: deleted, now included with EC 2.5.1.18 glutathione transferase EC 2.5.1.15: dihydropteroate synthase EC 2.5.1.16: spermidine synthase EC 2.5.1.17: cob(I)yrinic acid a,c-diamide adenosyltransferase EC 2.5.1.18: glutathione transferase EC 2.5.1.19: 3-phosphoshikimate 1-carboxyvinyltransferase EC 2.5.1.20: rubber cis-polyprenylcistransferase EC 2.5.1.21: squalene synthase EC 2.5.1.22: spermine synthase EC 2.5.1.23: sym-norspermidine synthase EC 2.5.1.24: discadenine synthase EC 2.5.1.25: tRNA-uridine aminocarboxypropyltransferase EC 2.5.1.26: alkylglycerone-phosphate synthase EC 2.5.1.27: adenylate dimethylallyltransferase EC 2.5.1.28: dimethylallylcistransferase EC 2.5.1.29: farnesyltranstransferase EC 2.5.1.30: trans-hexaprenyltranstransferase EC 2.5.1.31: ditrans,polycis-undecaprenyl-diphosphate synthase [(2E,6E)-farnesyl-diphosphate specific] EC 2.5.1.32: 15-cis-phytoene synthase EC 2.5.1.33: deleted, now covered by EC 2.5.1.82 hexaprenyl diphosphate synthase [geranylgeranyl-diphosphate specific] and EC 2.5.1.83 hexaprenyl diphosphate synthase [(2E,6E)-farnesyl-diphosphate specific] EC 2.5.1.34: tryptophan dimethylallyltransferase EC 2.5.1.35: aspulvinone dimethylallyltransferase EC 2.5.1.36: trihydroxypterocarpan dimethylallyltransferase EC 2.5.1.37: Now EC 4.4.1.20, leukotriene-C4 synthase EC 2.5.1.38: isonocardicin synthase EC 2.5.1.39: 4-hydroxybenzoate polyprenyltransferase EC 2.5.1.40: Now EC 4.2.3.9, aristolochene synthase EC 2.5.1.41: phosphoglycerol geranylgeranyltransferase EC 2.5.1.42: geranylgeranylglycerol-phosphate geranylgeranyltransferase EC 2.5.1.43: nicotianamine synthase EC 2.5.1.44: homospermidine synthase EC 2.5.1.45: homospermidine synthase (spermidine-specific) EC 2.5.1.46: deoxyhypusine synthase EC 2.5.1.47: cysteine synthase EC 2.5.1.48: cystathionine γ-synthase EC 2.5.1.49: O-acetylhomoserine aminocarboxypropyltransferase EC 2.5.1.50: zeatin 9-aminocarboxyethyltransferase EC 2.5.1.51: β-pyrazolylalanine synthase EC 2.5.1.52: L-mimosine synthase EC 2.5.1.53: uracilylalanine synthase EC 2.5.1.54: 3-deoxy-7-phosphoheptulonate synthase EC 2.5.1.55: 3-deoxy-8-phosphooctulonate synthase EC 2.5.1.56: N-acetylneuraminate synthase EC 2.5.1.57: N-acylneuraminate-9-phosphate synthase EC 2.5.1.58: protein farnesyltransferase EC 2.5.1.59: protein geranylgeranyltransferase type I EC 2.5.1.60: protein geranylgeranyltransferase type II EC 2.5.1.61: hydroxymethylbilane synthase EC 2.5.1.62: chlorophyll synthase EC 2.5.1.63: adenosyl-fluoride synthase EC 2.5.1.64: The reaction that was attributed to this enzyme is now known to be catalysed by two separate enzymes: EC 2.2.1.9 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylic-acid synthase and EC 4.2.99.20 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate synthase EC 2.5.1.65: O-phosphoserine sulfhydrylase EC 2.5.1.66: N2-(2-carboxyethyl)arginine synthase EC 2.5.1.67: chrysanthemyl diphosphate synthase EC 2.5.1.68: (2Z,6E)-farnesyl diphosphate synthase EC 2.5.1.69: lavandulyl diphosphate synthase EC 2.5.1.70: naringenin 8-dimethylallyltransferase EC 2.5.1.71: leachianone-G 2′′-dimethylallyltransferase EC 2.5.1.72: quinolinate synthase EC 2.5.1.73: O-phospho-L-seryl-tRNA:Cys-tRNA synthase EC 2.5.1.74: 1,4-dihydroxy-2-naphthoate polyprenyltransferase EC 2.5.1.75: tRNA dimethylallyltransferase EC 2.5.1.76: cysteate synthase EC 2.5.1.77: Now EC 2.5.1.147, 5-amino-6-(D-ribitylamino)uracil—L-tyrosine 4-methylphenol transferase and EC 4.3.1.32, 7,8-didemethyl-8-hydroxy-5-deazariboflavin synthase. EC 2.5.1.78: 6,7-dimethyl-8-ribityllumazine synthase EC 2.5.1.79: thermospermine synthase EC 2.5.1.80: 7-dimethylallyltryptophan synthase EC 2.5.1.81: geranylfarnesyl diphosphate synthase EC 2.5.1.82: hexaprenyl diphosphate synthase [geranylgeranyl-diphosphate specific] EC 2.5.1.83: hexaprenyl diphosphate synthase [(2E,6E)-farnesyl-diphosphate specific] EC 2.5.1.84: all-trans-nonaprenyl-diphosphate synthase (geranyl-diphosphate specific) EC 2.5.1.85: all-trans-nonaprenyl diphosphate synthase [geranylgeranyl-diphosphate specific] EC 2.5.1.86: trans,polycis-decaprenyl diphosphate synthase EC 2.5.1.87: ditrans,polycis-polyprenyl diphosphate synthase [(2E,6E)-farnesyl diphosphate specific] EC 2.5.1.88: trans,polycis-polyprenyl diphosphate synthase [(2Z,6E)-farnesyl diphosphate specific] EC 2.5.1.89: tritrans,polycis-undecaprenyl diphosphate synthase [geranylgeranyl-diphosphate specific] EC 2.5.1.90: all-trans-octaprenyl-diphosphate synthase EC 2.5.1.91: all-trans-decaprenyl-diphosphate synthase EC 2.5.1.92: (2Z,6Z)-farnesyl diphosphate synthase EC 2.5.1.93: 4-hydroxybenzoate geranyltransferase EC 2.5.1.94: adenosyl-chloride synthase EC 2.5.1.95: xanthan ketal pyruvate transferase EC 2.5.1.96: 4,4′-diapophytoene synthase EC 2.5.1.97: pseudaminic acid synthase EC 2.5.1.98: Rhizobium leguminosarum exopolysaccharide glucosyl ketal-pyruvate-transferase EC 2.5.1.99: The activity was an artifact caused by photoisomerization of the product of EC 2.5.1.32, 15-cis-phytoene synthase EC 2.5.1.100: fumigaclavine A dimethylallyltransferase EC 2.5.1.101: N,N′-diacetyllegionaminate synthase EC 2.5.1.102: geranyl-pyrophosphate—olivetolic acid geranyltransferase EC 2.5.1.103: presqualene diphosphate synthase EC 2.5.1.104: N1-aminopropylagmatine synthase EC 2.5.1.105: 7,8-dihydropterin-6-yl-methyl-4-(β-D-ribofuranosyl)aminobenzene 5′-phosphate synthase EC 2.5.1.106: tryprostatin B synthase EC 2.5.1.107: verruculogen prenyltransferase EC 2.5.1.108: 2-(3-amino-3-carboxypropyl)histidine synthase EC 2.5.1.109: brevianamide F prenyltransferase (deoxybrevianamide E-forming) EC 2.5.1.110: 12α,13α-dihydroxyfumitremorgin C prenyltransferase EC 2.5.1.111: 4-hydroxyphenylpyruvate 3-dimethylallyltransferase EC 2.5.1.112: adenylate dimethylallyltransferase (ADP/ATP-dependent) EC 2.5.1.113: [CysO sulfur-carrier protein]-thiocarboxylate-dependent cysteine synthase EC 2.5.1.114: tRNAPhe (4-demethylwyosine37-C7) aminocarboxypropyltransferase EC 2.5.1.115: homogentisate phytyltransferase EC 2.5.1.116: homogentisate geranylgeranyltransferase EC 2.5.1.117: homogentisate solanesyltransferase EC 2.5.1.118: β-(isoxazolin-5-on-2-yl)-L-alanine synthase EC 2.5.1.119: β-(isoxazolin-5-on-4-yl)-L-alanine synthase EC 2.5.1.120: aminodeoxyfutalosine synthase EC 2.5.1.121: 5,10-dihydrophenazine-1-carboxylate 9-dimethylallyltransferase EC 2.5.1.122: 4-O-dimethylallyl-L-tyrosine synthase EC 2.5.1.123: flaviolin linalyltransferase EC 2.5.1.124: 6-linalyl-2-O,3-dimethylflaviolin synthase EC 2.5.1.125: 7-geranyloxy-5-hydroxy-2-methoxy-3-methylnaphthalene-1,4-dione synthase EC 2.5.1.126: norspermine synthase EC 2.5.1.127: caldopentamine synthase EC 2.5.1.128: N4-bis(aminopropyl)spermidine synthase EC 2.5.1.129: flavin prenyltransferase EC 2.5.1.130: 2-carboxy-1,4-naphthoquinone phytyltransferase EC 2.5.1.131: (4-{4-[2-(γ-L-glutamylamino)ethyl]phenoxymethyl}furan-2-yl)methanamine synthase EC 2.5.1.132: 3-deoxy-D-glycero-D-galacto-nonulopyranosonate 9-phosphate synthase EC 2.5.1.133: bacteriochlorophyll a synthase EC 2.5.1.134: cystathionine β-synthase (O-acetyl-L-serine) EC 2.5.1.135: validamine 7-phosphate valienyltransferase EC 2.5.1.136: 2-acylphloroglucinol 4-prenyltransferase EC 2.5.1.137: 2-acyl-4-prenylphloroglucinol 6-prenyltransferase EC 2.5.1.138: coumarin 8-geranyltransferase EC 2.5.1.139: umbelliferone 6-dimethylallyltransferase EC 2.5.1.140: N-(2-amino-2-carboxyethyl)-L-glutamate synthase EC 2.5.1.141: heme o synthase EC 2.5.1.142: nerylneryl diphosphate synthase EC 2.5.1.143: pyridinium-3,5-biscarboxylic acid mononucleotide synthase EC 2.5.1.144: S-sulfo-L-cysteine synthase (O-acetyl-L-serine-dependent) EC 2.5.1.145: phosphatidylglycerol—prolipoprotein diacylglyceryl transferase EC 2.5.1.146: 3-geranyl-3-[(Z)-2-isocyanoethenyl]indole synthase EC 2.5.1.147: 5-amino-6-(D-ribitylamino)uracil—L-tyrosine 4-hydroxyphenyl transferase EC 2.5.1.148: lycopaoctaene synthase EC 2.5.1.149: lycopene elongase/hydratase (flavuxanthin-forming) EC 2.5.1.150: lycopene elongase/hydratase (dihydrobisanhydrobacterioruberin-forming) EC 2.5.1.151: alkylcobalamin dealkylase EC 2.5.1.152: D-histidine 2-aminobutanoyltransferase EC 2.5.1.153: adenosine tuberculosinyltransferase
Sources: en.wikipedia.org
I think most of them would rather drink weed killer than do this." He argued that the sale would stop a one-time budget problem without addressing spending, leaving a debt bomb for future generations. The legislature sided with Kennedy, and Jindal's plan dissolved.
On 12 November 1935 at the Hospital de Santa Marta in Lisbon, Moniz initiated the first of a series of operations on the brains of people with mental illnesses. The initial patients selected for the operation were provided by the medical director of Lisbon's Miguel Bombarda Mental Hospital, José de Matos Sobral Cid. As Moniz lacked training in neurosurgery and his hands were impaired by gout, the procedure was performed under general anaesthetic by Pedro Almeida Lima, who had previously assisted Moniz with his research on cerebral angiography. The intention was to remove some of the long fibres that connected the frontal lobes to other major brain centres. To this end, it was decided that Lima would trephine into the side of the skull and then inject ethanol into the "subcortical white matter of the prefrontal area" so as to destroy the connecting fibres, or association tracts, and create what Moniz termed a "frontal barrier". After the first operation was complete, Moniz considered it a success and, observing that the patient's depression had been relieved, he declared her "cured" although she was never, in fact, discharged from the mental hospital. Moniz and Lima persisted with this method of injecting alcohol into the frontal lobes for the next seven patients, but, after having to inject some patients on numerous occasions to elicit what they considered a favourable result, they modified the means by which they would section the frontal lobes.
== History == The prostate was first formally identified by Venetian anatomist Niccolò Massa in Anatomiae libri introductorius (Introduction to Anatomy) in 1536 and illustrated by Flemish anatomist Andreas Vesalius in Tabulae anatomicae sex (six anatomical tables) in 1538. Massa described it as a "glandular flesh upon which rests the neck of the bladder," and Vesalius as a "glandular body". The first time a word similar to prostate was used to describe the gland is credited to André du Laurens in 1600, who described it as a term already in use by anatomists at the time. The term was however used at least as early as 1549 by French surgeon Ambroise Pare. At the time, Du Laurens was describing what was considered to be a pair of organs (not the single two-lobed organ), and the Latin term prostatae that was used, meaning "one who stands before," "leader" or "guardian," was a mistranslation of the term for the Ancient Greek word used to describe the seminal vesicles, parastatai adenoeides, meaning "glandular assistants". Some have argued that surgeons in Ancient Greece and Rome must have at least seen the prostate as an anatomical entity, but other authors state that because prostatic anatomy varies greatly among species, and almost all anatomical dissection before the Renaissance was performed on animals, it is likely that the prostate was not recognized as a distinct organ. The term prostatae was taken rather than the grammatically correct prostator (singular) and prostatores (plural) because the gender of the Ancient Greek term was taken as female, when it was in fact male.
==== Medication ==== Statins, drugs that act to lower blood cholesterol, decrease the incidence and mortality rates of myocardial infarctions. They are often recommended in those at an elevated risk of cardiovascular diseases. Aspirin has been studied extensively in people considered at increased risk of myocardial infarction. Based on numerous studies in different groups (e.g. people with or without diabetes), there does not appear to be a benefit strong enough to outweigh the risk of excessive bleeding. Nevertheless, many clinical practice guidelines continue to recommend aspirin for primary prevention, and some researchers feel that those with very high cardiovascular risk but low risk of bleeding should continue to receive aspirin.
The speed of sound in helium is nearly three times the speed of sound in air. Because the natural resonance frequency of a gas-filled cavity is proportional to the speed of sound in the gas, when helium is inhaled, a corresponding increase occurs in the resonant frequencies of the vocal tract, which is the amplifier of vocal sound. This increase in the resonant frequency of the amplifier (the vocal tract) gives increased amplification to the high-frequency components of the sound wave produced by the direct vibration of the vocal folds, compared to the case when the voice box is filled with air. When a person speaks after inhaling helium gas, the muscles that control the voice box still move in the same way as when the voice box is filled with air; therefore the fundamental frequency (sometimes called pitch) produced by direct vibration of the vocal folds does not change. However, the high-frequency-preferred amplification causes a change in timbre of the amplified sound, resulting in a reedy, duck-like vocal quality. The opposite effect, lowering resonant frequencies, can be obtained by inhaling a dense gas such as sulfur hexafluoride or xenon.
Sources: en.wikipedia.org
Hydrolysis extent is often estimated by measuring the increase in soluble nitrogen or free amino groups relative to total nitrogen. The o-phthaldialdehyde method and trinitrobenzenesulfonic acid assay are common laboratory approaches. Values are method-dependent, so comparisons require the same assay and calculation.
Enzymatic cleavage can expose hydrophobic amino acid residues that interact with bitter taste receptors. The intensity depends on peptide sequence, hydrolysis extent, and further processing such as filtration or deamidation. Bitterness is not a reliable indicator of protein quality or allergenicity.
Moisture uptake, storage temperature, and packaging barrier properties are major factors. Residual lactose can participate in browning reactions when water activity and temperature rise. Shelf-life testing usually combines accelerated and real-time conditions to estimate change in color, solubility, and microbial stability.
Common laboratory methods measure free amino groups with TNBS or OPA reagents. The result is converted to a percentage using a reference standard and a defined protocol. Values are method-dependent, so comparisons require the same assay conditions.